Lupron Depot 3.75 mg Side Effects: FDA Label Numbers

Lupron Depot 3.75 mg side effects

leuprolide acetate for depot suspension · monthly intramuscular injection given by a healthcare provider, 3.75 mg · Label checked

In the label's endometriosis trials, the most common Lupron Depot 3.75 mg side effects were hot flashes or sweats (84% vs 29% on placebo), headache (32% vs 6%), vaginitis (28% vs 0%), depression or mood swings (22% vs 3%) and general pain.

Many reflect low estrogen. It has no boxed warning; loss of bone density, which limits treatment length, is its first listed risk.

At a glance

Boxed warning
None
Serious risk
Loss of bone mineral density (section 5.1)
Most common
Hot flashes/sweats*, 57% vs 29%
Serious risks listed
7
Form
Monthly intramuscular injection given by a healthcare provider, 3.75 mg
Log Lupron Depot 3.75 mg side effects next to each dose in Dose Track →

When does the label say to call your doctor?

From the Patient Counseling Information (section 17) that comes with Lupron Depot 3.75 mg:

  • Signs or symptoms of a severe skin reaction, such as fever, flu-like symptoms, sores in the mouth or other moist areas, a spreading rash or swollen lymph nodes: stop Lupron Depot 3.75 mg and contact your healthcare provider immediately.
  • Symptoms of an allergic reaction: seek appropriate medical care.
  • A convulsion (seizure): seek medical attention.
  • Thoughts or behaviors of concern, including new or worse depression: report them to your healthcare provider immediately.
  • A known or suspected pregnancy: tell your healthcare provider.

What are the most common Lupron Depot 3.75 mg side effects?

These are the label's own numbers from the Adverse Reactions section. Where the label compares with placebo (a dummy treatment), both columns are shown, so you can see how much more often a reaction happened on Lupron Depot 3.75 mg.

Danazol n=136Placebo n=31

Hot flashes/sweats*57% vs 29%
Headache*22% vs 6%
Vaginitis*17% vs 0%
Depression/emotional lability*20% vs 3%
General pain16% vs 3%

Reactions marked * are a possible effect of decreased estrogen. Danazol is another endometriosis medicine used as a comparator; the placebo group was small (31 women).

Show all 18 reactionsHide table
Table 2. Adverse Reactions Reported in ≥ 5% of Women with Endometriosis Taking LUPRON DEPOT 3.75 mg - 2 Studies [Section 6.1]
Adverse reactionLUPRON DEPOT 3.75 mg (%) N=166Danazol (%) N=136Placebo (%) N=31
Hot flashes/sweats*845729
Headache*32226
Vaginitis*28170
Depression/emotional lability*22203
General pain19163
Weight gain/loss13260
Nausea/vomiting13133
Decreased libido*1140
Dizziness1130
Acne10200
Skin reactions10153
Joint disorder*880
Edema7133
Paresthesias780
GI disturbances*763
Neuromuscular disorders*7130
Breast changes/tenderness/pain*690
Nervousness*580
Show the label table (10 rows)Hide table
Table 3. Adverse Reactions Reported in ≥ 5% of Women with Uterine Fibroids (4 Studies) Taking LUPRON DEPOT 3.75 mg [Section 6.1]
Adverse reactionLUPRON DEPOT 3.75 mg (%) N=166Placebo (%) N=163
Hot flashes/sweats*7318
Headache*2618
Vaginitis*112
Depression/emotional lability*114
Asthenia85
General pain86
Joint disorder*83
Edema51
Nausea/vomiting54
Nervousness*51

Reactions marked * are a possible effect of decreased estrogen. Asthenia means weakness or lack of energy.

Show the label table (12 rows)Hide table
Selected rows from Table 4. Adverse Reactions Occurring in the First Six Months of Treatment in ≥ 5% of Women with Endometriosis [Section 6.1]
Adverse reactionControlled study LD-Only (%) N=51Controlled study LD/N (%) N=55Open-label study LD/N (%) N=136
Hot flashes/Sweats988757
Headache/Migraine655146
Depression/Emotional Lability312734
Insomnia/Sleep Disorder311315
Nausea/Vomiting252913
Pain242921
Vaginitis20158
Asthenia181811
Dizziness/Vertigo16117
Weight Gain12134
Decreased Libido1047
Androgen-Like Effects (acne, alopecia)4518

LD-Only = Lupron Depot 3.75 mg alone; LD/N = Lupron Depot 3.75 mg plus norethindrone acetate 5 mg daily (add-back). No placebo group.

Other numbers in the Adverse Reactions section

  • Section 14.1Lumbar spine bone density over 52 weeks: -6.3% on Lupron Depot 3.75 mg alone vs -1.0% with norethindrone add-back (controlled study) and -1.1% (open-label study) (Table 9). Twelve months after stopping, it was still -2.2% in the Lupron-only group (Table 10).
  • Section 14.2In women with fibroids, 3 months of Lupron Depot 3.75 mg lowered spinal bone density by a mean 2.7%, with a trend toward recovery 6 months after stopping.
Show 4 more findingsShow fewer
  • Section 6.1In the 6 monotherapy studies, 1.8% stopped early because of hot flashes. In the 1-year add-back studies, 18% stopped in each arm of the controlled study and 13% in the open-label study.
  • Section 6.1Serious adverse reactions: urinary tract infection (1.9%), kidney stone (0.7%) and depression (0.7%).
  • Section 6.1Lipids: triglycerides rose above normal in 12% of women with endometriosis. With norethindrone add-back, HDL cholesterol fell about 15% to 19% at week 24 and the LDL/HDL ratio rose about 39% to 43% (Table 6); levels returned to baseline after treatment.
  • Section 6.2Reported after approval across Lupron Depot products: serious skin reactions, anaphylaxis, mood swings including suicidal thoughts, convulsions, serious liver injury, spinal fracture, blood clots, heart attack, stroke and pituitary apoplexy (often within 2 weeks of the first dose).

What serious risks does the Lupron Depot 3.75 mg label warn about?

The Warnings and Precautions part of the label lists these. Each line gives the label's heading and what it means in plain words.

  • Section 5.1Loss of bone mineral density. Lupron Depot 3.75 mg causes a low-estrogen state that reduces bone density, and some loss may not reverse after stopping. Treatment length is limited for this reason. For endometriosis, norethindrone add-back reduces the loss; retreatment is only with add-back, after a bone density check.
  • Section 5.2Harm to an unborn baby. It may cause fetal harm and is contraindicated in pregnancy. Pregnancy is excluded before starting if clinically indicated. It is not a contraceptive; a non-hormonal method is advised if contraception is needed (section 8.3).
  • Section 5.3Severe skin reactions. Stevens-Johnson syndrome, toxic epidermal necrolysis, DRESS and AGEP have been reported with GnRH agonists, including Lupron Depot. It is stopped if one is suspected and not restarted if confirmed.
  • Section 5.4Allergic reactions. Anaphylaxis has been reported. Asthma events occurred in women with past asthma, sinusitis or allergies.
Show 3 more risksShow fewer
  • Section 5.5Initial flare of symptoms. After the first dose, sex hormones briefly rise above baseline, so symptoms may get worse in the first days before easing with continued treatment.
  • Section 5.6Convulsions. Seizures have been reported after approval in women on GnRH agonists, with and without other medicines or conditions.
  • Section 5.7Depression. Depression may start or worsen, especially with a history of depression. Women are watched closely, and new or worsening depression may lead to referral.

Does Lupron Depot 3.75 mg have a boxed warning?

No. The current Lupron Depot 3.75 mg label has no boxed warning.

How do I keep track of side effects in Dose Track?

Dose Track has a side-effect log. Each entry records the symptom, a severity (none, mild, moderate, severe or life-threatening), the date and an optional note, and can be tied to a specific dose or logged on its own.

Read moreRead less

The history screen shows what you logged over time, which makes it easier to tell your prescriber when a reaction started and whether it is easing. The app records what you enter; it does not judge whether a symptom is serious. For anything on the label's call-your-doctor list, call your doctor.

Frequently asked questions

What are the most common side effects of Lupron Depot 3.75 mg?

In endometriosis trials: hot flashes or sweats (84% vs 29% on placebo), headache (32% vs 6%), vaginitis (28% vs 0%), depression or mood swings (22% vs 3%) and general pain (19% vs 3%) (section 6.1, Table 2).

Does Lupron Depot cause bone loss?

Yes. Spinal bone density fell 6.3% over a year on Lupron Depot 3.75 mg alone vs about 1% with norethindrone add-back, and some loss may not reverse (section 5.1; section 14.1, Table 9).

Does norethindrone add-back reduce Lupron side effects?

In the controlled study, hot flashes were 87% with add-back vs 98% without, and sleep problems 13% vs 31% (section 6.1, Table 4). Add-back also reduced bone loss (section 5.1).

Why do symptoms get worse after the first Lupron shot?

The label says sex hormones rise above baseline for a short time after the first dose, so symptoms may increase in the first days and then ease with continued treatment (section 5.5).

Does Lupron Depot 3.75 mg have a boxed warning?

No. The current label has no boxed warning. Its warnings cover bone loss, harm in pregnancy, severe skin reactions, allergic reactions, the initial flare, convulsions and depression (section 5).

Show similar medicinesShow fewer

Sources

  1. LUPRON DEPOT 3.75 mg (leuprolide acetate for depot suspension), for intramuscular use, prescribing information. AbbVie. DailyMed, version published September 22, 2025. DailyMed setid 00c486b0-bd7b-4898-834d-8c656e5e73cb
What Lupron Depot 3.75 mg is approved forHide

Lupron Depot 3.75 mg is a GnRH agonist approved to manage endometriosis, including pain relief and shrinking lesions, alone or with norethindrone acetate add-back; and, with iron, to improve blood counts before surgery in women with anemia from fibroids when 3 months of hormone suppression is needed (sections 1.1 and 1.2). This page covers only the 3.75 mg monthly gynecologic label, not the 11.25 mg or prostate cancer labels.

This page is what the FDA label says, in plain words. It is not medical advice. Follow your prescriber, and ask them or your pharmacist about anything here.

All side-effect pages · Dosing schedules · Missed dose guides · Compound guides